4 transcripts
CRVS
Earnings call transcript
NASDAQ
2024 Q2
6 Aug 24
continues to grow as another patient in our Phase I/Ib trial experienced continued tumor regression and recently achieved a complete response after
CRVS
Earnings call transcript
NASDAQ
2024 Q1
6 May 24
Phase I/Ib trial recently achieved objective responses at first follow-up. Second, our placebo-controlled Phase I trial of soquelitinib for patients
CRVS
Earnings call transcript
NASDAQ
2023 Q4
19 Mar 24
reported partial response of approximately 80% target lesion reduction after 9 weeks of therapy subsequently converted to a complete response at 18
CRVS
Earnings call transcript
NASDAQ
2023 Q2
8 Aug 23
its modulation of T cell differentiation. Three, in the clinic, we have shown monotherapy antitumor activity with durable responses in very sick
- Prev
- 1
- Next